Abstract bekijken

Deze abstract is toegekend aan sessie AOB Free Papers 1
Type presentatieOral presentation
TitelHave we gone down a new road with Akantior® in the treatment of Acanthamoeba keratitis?
DoelThis case series evaluates the efficacy and tolerability of Akantior® (polyhexanide 0.08%) as a novel treatment for Acanthamoeba keratitis.
MethodesFour patients with confirmed Acanthamoeba keratitis were treated with Akantior® at the University Hospital Leuven between 2024-2025.
ResultatenFollowing treatment with Akantior®, two of the four patients showed complete remission of their infectious keratitis. The third patient discontinued therapy due to intolerance, with worsening symptoms reporting increased irritation and conjunctival hyperaemia. The fourth patient who was recently initiated on Akantior® is currently closely monitored.
ConclusieThe novel drug Akantior® (polyhexanide 0.08%) works through two mechanisms: it disrupts the outer membrane of the Acanthamoeba cell, causing cell death; while also damaging the genetic material, preventing replication. Previous research shows that polyhexanide 0.08% monotherapy is non-inferior, and potentially even superior, to currently used dual therapy (polyhexanide 0.02% plus propamidine). The commercial availability of Akantior® provides an important advantage over compounded formulations, moreover as polyhexanide is currently not available in Belgium as raw material. The validation of clinical results, together with pricing and potential reimbursement in Belgium, will determine whether Akantior® secures its long-term position in the field.
BelangenverstrengelingNee
Auteurs 1
InitialenE
NaamVerleyen
InstituutUZ Leuven
StadLeuven
Auteurs 2
InitialenH
NaamDelbeke
InstituutUZ Leuven
StadLeuven
top ^